Pacific Biosciences of California, Inc. Peer Comparison
Metric | Value | Ranking | ||||||
---|---|---|---|---|---|---|---|---|
Market Cap | $372.5 Million | 4/6 | CRSP $3.7B |
TWST $2.8B |
NTLA $968.6M |
PACB $372.5M |
EDIT $98.2M |
NVTA $5.7M |
Gross Margin | 25% | 4/6 | NTLA 100% |
TWST 45% |
NVTA 32% |
PACB 25% |
EDIT -100% |
CRSP -100% |
Profit Margin | -100% | 2/6 | TWST -41% |
PACB -100% |
NVTA -100% |
EDIT -100% |
NTLA -100% |
CRSP -100% |
EBITDA margin | -148% | 2/6 | TWST -43% |
PACB -148% |
NVTA -808% |
NTLA -1490% |
CRSP -18294% |
EDIT -101870% |
Quarterly Revenue | $40.0 Million | 3/6 | NVTA $121.2M |
TWST $84.7M |
PACB $40.0M |
NTLA $9.1M |
CRSP $602,000 |
EDIT $61,000 |
Quarterly Earnings | -$60.7 Million | 2/6 | TWST -$34.7M |
PACB -$60.7M |
EDIT -$62.1M |
CRSP -$85.9M |
NTLA -$135.7M |
NVTA -$942.1M |
Quarterly Free Cash Flow | -$44.7 Million | 1/6 | PACB -$44.7M |
EDIT -$55.5M |
NVTA -$66.9M |
NTLA -$86.1M |
CRSP -$107.1M |
TWST -$0 |
Trailing 4 Quarters Revenue | $173.1 Million | 4/6 | NVTA $481.6M |
TWST $313.0M |
CRSP $201.6M |
PACB $173.1M |
EDIT $61.8M |
NTLA $43.1M |
Trailing 4 Quarters Earnings | -$394.2 Million | 4/6 | NVTA $121.2M |
TWST $84.7M |
PACB $40.0M |
NTLA $9.1M |
CRSP $602,000 |
EDIT $61,000 |
Quarterly Earnings Growth | 9% | 3/6 | TWST 25% |
CRSP 23% |
PACB 9% |
NTLA -11% |
EDIT -38% |
NVTA -213% |
Annual Earnings Growth | -43% | 6/6 | NVTA 82% |
CRSP 31% |
TWST 4% |
NTLA -6% |
EDIT -27% |
PACB -43% |
Quarterly Revenue Growth | -28% | 6/6 | TWST 27% |
EDIT 0% |
CRSP 0% |
NVTA -9% |
NTLA -24% |
PACB -28% |
Annual Revenue Growth | -13% | 5/6 | EDIT 613% |
TWST 21% |
CRSP -4% |
NVTA -11% |
PACB -13% |
NTLA -18% |
Cash On Hand | $78.0 Million | 6/6 | TWST $226.3M |
CRSP $225.7M |
NVTA $158.0M |
NTLA $120.5M |
EDIT $95.8M |
PACB $78.0M |
Short Term Debt | $10.7 Million | 6/6 | NVTA $21.6M |
NTLA $19.2M |
CRSP $16.9M |
EDIT $16.4M |
TWST $14.8M |
PACB $10.7M |
Long Term Debt | $910.1 Million | 2/6 | NVTA $1.5B |
PACB $910.1M |
CRSP $210.7M |
NTLA $82.4M |
TWST $70.2M |
EDIT $22.1M |
PE | -1.00 | 1/6 | PACB -1.00 |
NVTA -1.00 |
EDIT -1.00 |
NTLA -1.00 |
CRSP -1.00 |
TWST -1.00 |
PS | 2.15 | 4/6 | NTLA 22.48 |
CRSP 18.33 |
TWST 8.81 |
PACB 2.15 |
EDIT 1.59 |
NVTA 0.01 |
PB | 0.82 | 4/6 | TWST 5.83 |
CRSP 1.91 |
NTLA 1.01 |
PACB 0.82 |
EDIT 0.56 |
NVTA 0.00 |
PC | 4.78 | 4/6 | CRSP 16.38 |
TWST 12.18 |
NTLA 8.04 |
PACB 4.78 |
EDIT 1.03 |
NVTA 0.04 |
Liabilities to Equity | 2.20 | 1/6 | PACB 2.20 |
EDIT 0.87 |
TWST 0.30 |
NTLA 0.22 |
CRSP 0.16 |
NVTA 0.00 |
ROA | -0.27 | 2/6 | CRSP -11% | PACB -27% | TWST -34% | NTLA -45% | EDIT -64% | NVTA -269% |
ROE | -0.87 | 5/6 | NVTA 133% |
CRSP -12% |
TWST -44% |
NTLA -54% |
PACB -87% |
EDIT -120% |
Current Ratio | 1.45 | 5/6 | CRSP 7.13 |
NTLA 5.57 |
TWST 4.34 |
EDIT 2.16 |
PACB 1.45 |
NVTA 0.33 |
Quick Ratio | 0.08 | 6/6 | PACB -1.00 |
NVTA -1.00 |
EDIT -1.00 |
NTLA -1.00 |
CRSP -1.00 |
TWST -1.00 |
Long Term Debt to Equity | 2.01 | 1/6 | PACB} 2.01 |
TWST} 0.15 |
EDIT} 0.13 |
CRSP} 0.11 |
NTLA} 0.09 |
NVTA} -1.37 |
Debt to Equity | 2.03 | 1/6 | PACB 2.03 |
EDIT 0.22 |
TWST 0.18 |
CRSP 0.12 |
NTLA 0.11 |
NVTA -1.39 |
Burn Rate | 0.78 | 5/6 | TWST 5.50 |
CRSP 2.29 |
EDIT 1.43 |
NTLA 0.84 |
PACB 0.78 |
NVTA 0.16 |
Cash to Cap | 0.21 | 3/6 | NVTA 27.58 |
EDIT 0.98 |
PACB 0.21 |
NTLA 0.12 |
TWST 0.08 |
CRSP 0.06 |
CCR | 0.74 | 3/6 | CRSP 1.25 |
EDIT 0.89 |
PACB 0.74 |
NTLA 0.63 |
NVTA 0.07 |
TWST |
EV to EBITDA | -20.51 | 4/6 | EDIT} -0.66 |
NVTA} -1.38 |
NTLA} -7.00 |
PACB} -20.51 |
CRSP} -33.58 |
TWST} -72.54 |
EV to Revenue | 7.02 | 4/6 | NTLA 22.04 |
CRSP 18.34 |
TWST 8.35 |
PACB 7.02 |
NVTA 2.82 |
EDIT 0.66 |